News

Media Archives

News

Media Archives

PIE Magazine | Practical Paths to Vision Restoration, Turning Bipolar Cells into Light Catchers – Dr. Samarendra Mohanty and Dr. Stephen Tsang Talk

•
October 21, 2025

Opthalmology Times | Video Interview: AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt Disease

•
October 20, 2025

Retinal Physician | Article and Video Interview with Allen C. Ho, MD: Optogenetic Therapy Offers Renewed Hope in Retinitis Pigmentosa

•
October 19, 2025

Pie Magazine | Nanoscope Kickstarts BLA Submission for Restorative RP Therapy, Adds to Advisory Board

•
July 15, 2025

Eyewire News | Nanoscope Initiates Rolling Submission of BLA to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat RP

•
July 14, 2025

Modern Retina | FDA grants Nanoscope rolling BLA submission of MCO-010

•
July 14, 2025

Healio Ocular Surgery News | Nanoscope begins rolling submission of biologics license application for RP gene therapy

•
July 14, 2025

Medscape: The Women in Healthcare Leadership Podcast Series featuring Nanoscope CEO, Sulagna Bhattacharya

•
July 2, 2025

Modern Retina: Victor Gonzalez, MD, shares research findings on vision restoration in patients with retinitis pigmentosa

•
June 21, 2025

Modern Retina: Optogenetics for retinal disease

•
June 15, 2025

Healio-Ocular Surgery News: Gene therapy shows long-term visual acuity improvements in retinitis pigmentosa

•
June 13, 2025

Ophthalmology Breaking News: Nanoscope Therapeutics Publishes Clinical Data Demonstrating Vision Restoration in Retinitis Pigmentosa

•
March 28, 2025

Ophthalmology 360: VIDEO: Two-year results of RESTORE study highlight a mutation-agnostic gene therapy for retinitis pigmentosa

•
October 31, 2024

Healio/Ocular Surgery News: VIDEO: Nanoscope Therapeutics shares status update

•
October 28, 2024

HCP Live: VIDEO: Allen C. Ho, MD: Efficacy, Safety of MCO-010 for Retinitis Pigmentosa at 2 Years

•
October 24, 2024

Healio/Ocular Surgery News: VIDEO: Optogenetic therapy trial in retinitis pigmentosa meets safety, efficacy endpoints

•
October 21, 2024

Ophthalmology Times: AAO 2024: New gene therapy shows promise for treatment of retinitis pigmentosa

•
October 20, 2024

Ocular Surgery News: VIDEO: Optogenetic therapy shows promise for inherited retinal dystrophies

•
October 1, 2024

Max-Planck-Gesellschft: Nanoscope Therapeutics licenses optogenetic technology

•
September 30, 2024

HCP Live: Nanoscope Reports Positive End-of-Phase 2 Meeting for MCO-010 Gene Therapy

•
September 13, 2024

Retina Specialist: ARVO 2024 Highlights – Optogenetic therapy for retinitis pigmentosa yields BCVA improvement at one year

•
August 21, 2024

Ocular Surgery News: VIDEO: MCO-010 for retinitis pigmentosa improves vision in phase 2b/3 study

•
August 11, 2024

Modern Retina: ASRS 2024: RESTORE trial 100-week results presented by Dr. Michael Singer

•
July 27, 2024

Ocular Surgery News: VIDEO: Optogenetic therapy shows vision improvements, safety at 12 months

•
May 7, 2024

Longevity Technology: Nanoscope targets FDA approval following positive gene therapy trial results

•
March 28, 2024

Pharmaceutical Technology: Nanoscope Therapeutics exhibits positive top-line Phase IIb results for MCO-010

•
March 28, 2024

Ocular Surgery News: Gene therapy improves vision in patients with retinitis pigmentosa in phaase 2b trial

•
March 27, 2024

Modern Retina: Nanoscope Therapeutics lead candidate MCO-010 meets endpoints in RESTORE trial for retinitis pigmentosa

•
March 26, 2024

Pharmaphorum: Nanoscope preps filing for retinitis pigmentosa gene therapy

•
March 26, 2024

Fierce Biotech: Nanoscope eyes market after gene therapy restores vision for patients with retinal disease

•
March 26, 2024

Modern Retina : https://www.modernretina.com/view/mco-010-optogenetic-gene-therapy-for-severe-vision-loss-in-stargardt-disease

•
November 20, 2023

The Healthcare Technology Report: The Top 25 Women Leaders in Biotechnology of 2023

•
November 20, 2023

Eyewire.com : Nanoscope Therapeutics Wins ‘Best of Show’ Award at AAO Eyecelerator 2023

•
November 10, 2023

Healio : VIDEO: Optogenetic Therapy Shows Promise in Advanced Retinitis Pigmentosa

•
October 17, 2023

Modern Retina: Euretina 2024: Safety and efficacy through week 48 in the Phase 2a STARLIGHT clinical trial

•
October 6, 2023

Modern Retina : Gene Therapy: What’s to Come?

•
September 18, 2023

Retina Today : The Latest in Gene Therapy Clinical Trials for IRD

•
August 21, 2023

Ophthalmology Times : ASRS 2023: The STARLIGHT Study

•
August 6, 2023

Healio : Video: Early Data on Optogenetic Therapy in Stargardt Disease Promising

•
August 6, 2023

Eye on the Cure Podcast Episode #46 : Aaron Osborne, MD, Chief Medical Officer and Chief Development Office of Nanoscope Therapeutics

•
May 24, 2023

Clinical Trials Arena : Nanoscope reveals key efficacy data from Phase IIb ophthalmology trial

•
April 28, 2023

Ophthalmology Times : Nanoscope Therapeutics presents results from phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

•
April 28, 2023

Global Genes: Nanoscope Reports Positive Topline Results from Phase 2b Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

•
April 10, 2023

Clinical Trials Arena: Nanoscope’s Gene Therapy Nabs Phase II Win in Retinitis Pigmentosa

•
March 30, 2023

Fierce Biotech: Nanoscope’s Phase 2Win for Gene Therapy Shows Potential of Light-sensitive Approach to Eye Disease

•
March 30, 2023

Dallas Innovates: Nanoscope Therapeutics bolsters board with addition of ophthalmic veteran as strategic adviser

•
March 22, 2023

The Future 50 in Dallas-Fort Worth 2023: Meet the Game-Changing Disruptors Driving Innovation and Impace

•
March 17, 2023

Modern Retina: Nanoscope Therapeutics announces WHO selection of ‘sonpiretigene isteparvovec’ as international nonproprietary name for MCO-010

•
March 1, 2023

CGT Live: 10 Cell and Gene Therapies to Watch in 2023

•
January 25, 2023

Modern Retina: FDA grants fast track designation to Nanoscope Therapeutics for MCO-010 for the treatment of retinitis pigmentosa

•
October 18, 2022

Ocular Surgery News: Retinitis Pigmentosa Treatment Receives Fast Track Designation

•
October 18, 2022

Euretina Congress Daily: Making Headway in the Battle Against Inherited Retinal Disease

•
September 15, 2022

Ophthalmology Times: Enrollment Complete in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

•
September 13, 2022

Meet the 43 Finalists for the 2022 Tech Titans Awards

•
September 9, 2022

CityBiz: TechFW Member Nanoscope Starts Second Stage 2 Trial

•
July 26, 2022

CGT Live: Nanoscope Gene Therapy Continues Progress in Stargardt Disease

•
July 26, 2022

Ocular Surgery News: Phase 2 gene therapy trial for Stargardt disease underway

•
July 26, 2022

Ophthalmology Times: Nanoscope Therapeutics announces first patient dosed in STARLIGHT Phase 2 clinical trial of MCO-010 optogenetic gene therapy for Stargardt disease

•
July 25, 2022

Retina Synthesis: Optogenetics Interview with Samarendra Mohanty, PhD and Charles Wykoff, MD

•
May 3, 2022

Healio: Gene therapy platform for Stargardt macular degeneration receives IND clearance

•
January 25, 2022

Ophthalmology Times: Nanoscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt patients

•
January 25, 2022

Photonics West BIOS Show Daily: Optogenetics a Promising Route to Vision Restoration

•
January 22, 2022

Ft Worth Business Press: TechFW Client Nanoscope Receives $1.5M Grant to Move Macular Degeneration Therapy Forward

•
September 21, 2021

Dallas Innovates: Nanoscope Awarded $1.5 Million Grant for Eyesight Gene Therapy as it ‘Takes Steps to Go Public’

•
September 17, 2021

The Science Advisory Board: Optogenetic gene therapy provides hope for retinitis pigmentosa patients

•
August 6, 2021

Fort Worth Business Press: First patient receives innovative gene therapy eye treatment from TechFW client

•
August 4, 2021

Retina Today: AAV Gene Therapy Trials to Watch

•
August 3, 2021

BIO.org: The Pandemic Highlights Need for More Women Scientists

•
July 28, 2021

Modern Retina: Optogenetic Gene Trial Begins, First Patient Dosed

•
July 28, 2021

Ophthalmology Times: First patient dosed in optogenetic gene therapy trial

•
July 19, 2021

Fighting Blindness Foundation: Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy

•
July 19, 2021

Fort Worth Inc.: Bedford’s Nanoscope Begins Human Trial of Drug for Retinitis Pigmentosa

•
July 19, 2021

BioSpace: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b Clinical Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with RP

•
June 24, 2021

Ft. Worth Business Press: Nanoscope Therapeutics cleared to open Phase 2b clinical trial for vision therapy

•
June 23, 2021

Dallas Morning News: Bedford biotech’s eyesight-restoring gene therapy received FDA approval to test in the U.S.

•
June 23, 2021

Dallas Innovates: Bedford Biotech Restores “Meaningful Vision” in Blind Patients With Gene Therapy—and May Soon Go Public

•
June 22, 2021

Forbes: What is ‘Optogenetics’? Behind the Technology That’s Bringing Sight to The Blind.

•
June 16, 2021

Fort Worth Business: North Texas biotechnology company shows vision improvement via gene therapy

•
June 4, 2021

Dallas Morning News: Bedford Biotech’s Gene Therapy Improves Sight for 11 Patients with Rare Genetic Retinal Disorder

•
June 4, 2021

Citybiz: Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosa

•
June 3, 2021

Opthalmology Times: Optogenetic gene therapy restores vision in 11 RP patients

•
June 3, 2021

Ocular Surgery News: Optogenetics, goggles increase visual perception in case of inherited retinal dystrophy

•
June 3, 2021

Nature Gene Therapy: Sensitization of ON-bipolar cells with ambient light activatable multi-characteristic opsin rescues vision in mice

•
May 19, 2021

14 Emerging Tech Trends for 2021—and Dallas-Area Companies That Are Innovating for the Future

•
March 6, 2021

Nature: Light-activated genetic therapy to treat blindness enters clinic

•
February 9, 2021

Injection that could improve fading sight in aging eyes starts human trials after curing blindness in mice

•
October 22, 2020

Human trials for genetic jab that lets blind mice see again

•
October 22, 2020

Nanoscope Therapeutics Closes Series A, Names Alvaro Guillem as Chairman

•
July 21, 2020

Two TechFW Clients Receive Awards from NASA and the National Eye Institute

•
June 1, 2020

Dallas Morning News: Bedford biomedical firm wins major backing for tech that could restore damaged retinas

•
September 24, 2018